Our results in preclinical ovarian cancer models support further testing of BA in clinical trials for HGSC patients with potential stratification of patients having high TGF-β in ascites or circulating biomarkers related to TGF-β. This evidence concerns the gene TGFB1 and ovarian carcinoma.